With FDA clearance secured for its Bluetooth-connected insulin dose-tracking technology, Eli Lilly is ready to pick up the tempo.
The Big Pharma plans to begin rolling out its Tempo diabetes management platform in select U.S. clinics in the final weeks of this year, before expanding the technology’s reach across the country throughout 2023, Lilly announced Monday.
The platform combines Lilly’s prefilled, disposable Tempo Pens for insulin delivery with the compatible TempoSmart mobile app and the Tempo Smart Button, which is designed to track the pens’ insulin dosages.
Read more at: https://www.fiercebiotech.com/medtech/eli-lilly-lines-launch-diabetes-management-platform-tracks-insulin-pen-use-blood-sugar
